Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for lymphoma patients: personalized treatment targets cancer without chemo

NCT ID NCT06793189

First seen Apr 08, 2026 · Last updated May 18, 2026 · Updated 5 times

Summary

This study tests a personalized treatment approach for people with untreated marginal zone lymphoma, a slow-growing blood cancer. About 145 participants will receive targeted therapy based on their individual risk score. The goal is to see if this tailored treatment can keep the cancer from coming back for at least two years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA(MZL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Affiliated First Hospital of China Medical University

    RECRUITING

    Shenyang, Liaoning, China

    Contact Email: •••••@•••••

  • Peking University Third Hospital

    RECRUITING

    Beijing, China

    Contact Email: •••••@•••••

  • Shanghai Ruijin Hospital

    RECRUITING

    Shanghai, China, 200025, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.